Reported 0 shares, down 61,959 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 6892000 |
| 2022-03-31 | 4765000 |
| 2022-06-30 | 5703000 |
| 2022-09-30 | 5575000 |
| 2022-12-31 | 2825410 |
| 2023-03-31 | 2914881 |
| 2023-06-30 | 187736 |
| 2023-09-30 | 86743 |
| 2023-12-31 | 146843 |
| 2024-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2024 | Reduced | 0 | -61,959 (-100.0%) | 0 | $0 | 2024-05-15 | |
| Q4 2023 | Unchanged | 61,959 | 0 (0.0%) | < 0.01% | $146,843 | 2024-02-14 | |
| Q3 2023 | Unchanged | 61,959 | 0 (0.0%) | < 0.01% | $86,743 | 2023-11-14 | |
| Q2 2023 | Reduced | 61,959 | -404,422 (-86.7%) | < 0.01% | $187,736 | 2023-08-14 | |
| Q1 2023 | Added | 466,381 | +3,199 (0.7%) | < 0.01% | $2,914,881 | 2023-05-15 | |
| Q4 2022 | Reduced | 463,182 | -3,339 (-0.7%) | < 0.01% | $2,825,410 | 2023-02-14 | |
| Q3 2022 | Added | 466,521 | +14,243 (3.1%) | < 0.01% | $5,575,000 | 2022-11-15 | |
| Q2 2022 | Added | 452,278 | +29,124 (6.9%) | < 0.01% | $5,703,000 | 2022-08-15 | |
| Q1 2022 | Added | 423,154 | +34,224 (8.8%) | < 0.01% | $4,765,000 | 2022-05-16 | |
| Q4 2021 | Added | 388,930 | +56,355 (16.9%) | < 0.01% | $6,892,000 | 2022-02-14 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
77 managers reported KINNATE BIOPHARMA INC for Q1 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Foresite Capital Management IV LLC | Unchanged | 9,671,643 | 0 | 13.0% | $25,726,570 | 14 qtrs |
| ORBIMED ADVISORS LLC | Unchanged | 8,009,729 | 0 | 0.39% | $21,305,879 | 14 qtrs |
| Foresite Capital Management V LLC | Unchanged | 3,525,957 | 0 | 8.8% | $9,379,046 | 14 qtrs |
| Lynx1 Capital Management LP | Reduced | 1,981,106 | -15,900 | 1.36% | $5,269,742 | 9 qtrs |
| VIKING GLOBAL INVESTORS LP | Unchanged | 1,820,462 | 0 | 0.02% | $4,842,429 | 14 qtrs |
| VANGUARD GROUP INC | Added | 1,076,789 | +33,879 | < 0.01% | $2,864,259 | 14 qtrs |
| DELTEC ASSET MANAGEMENT LLC | New | 1,039,800 | +1,039,800 | 0.55% | $2,765,868 | 1 qtr |
| TANG CAPITAL MANAGEMENT LLC | Reduced | 977,626 | -1,624,021 | 0.27% | $2,600,485 | 2 qtrs |
| ACADIAN ASSET MANAGEMENT LLC | Added | 964,881 | +134,388 | < 0.01% | $2,565,000 | 8 qtrs |
| RENAISSANCE TECHNOLOGIES LLC | Added | 887,740 | +312,761 | < 0.01% | $2,361,000 | 12 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2024
- Filed
- May 15, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.